Podcast

Speaking of Urology: A HIFU expert discusses his treatment criteria

Author(s):

Urology Times staff

In this episode, Samuel J. Peretsman, MD, describes his background and experience with HIFU as a treatment for patients with prostate cancer, and also discusses his treatment criteria for the modality.

Be sure to listen our first episode as well:

Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Related Videos
Vanita Gaglani, RPT, answers a question during a video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Trial of immune therapy in mCRPC expands enrollment to VA medical center
January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke
Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
January 27th 2025

Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment

Mohit Khera, MD, MBA, MPH
“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Health-related QOL is comparable among ARPI regimens for CSPC
January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke
At 25 weeks, FACT-P total score remained comparable between the arms.
EU approves Mona Lisa 2.0 robotic system for prostate cancer
January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke
The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.
© 2025 MJH Life Sciences

All rights reserved.